In our laboratory we test for antibodies by the SeraSpot, IFA and ELISA techniques. In general, the SeraSpot has a higher sensitivity and specificity in detecting Borrelia antibodies compared to the ELISA and IFA test technique.
However the development of Borrelia burgdorferi-specific antibodies can be avoided and suppressed by antibiotic therapies in recent infections. These cases can be detected by the EliSpot for tick-borne infections.
New retrospective study confirming the Lyme SeraSpot as a reliable and robust test system:
"Our evaluation data confirm that new multiplex assay generations such as SeraSpot®Anti-Borrelia
IgG/IgM are reliable and robust test systems suitable for application as confirmatory tests for serodiagnosis of
Lyme borreliosis. "
Von Baehr et al.: Evaluation of a New Multiparametric Microspot Array for Serodiagnosis of Lyme Borreliosis in: Clin. Lab. 2015;61
Borrelia infections cannot be completely excluded due to negative serological tests:
Laboratories should test for "VIsE" (Variable major protein-like sequence Expressed) in the ELISA and SeraSpot test systems. VIsE describes the ability of the 'chameleon' Borrelia burgdorferi to constantly change its surface protein structure VIsE in vivo in order to avoid being identified by the immune system. VIsE has the highest sensitivity when searching for antibodies against Borrelia burgdorferi.
The SeraSpot MicroArray analyzes the following Borrelia burgdorferi IgG- and IgM-antibodies and Borrelia burgdorferi subspecies:
VlsE (B.b. afzelii), p39 (B.b. afzelii), p58 (B.b. garinii), p100 (B.b. afzelii), OspC (B.b. afzelii + B.b. garinii + B.b. sensu stricto), DbpA (B.b. afzelii + B.b. garinii + B.b. sensu stricto).